Vaderis Therapeutics AG
Vaderis is a clinical stage biotech based in Basel, specialising in rare diseases associated with vascular malformations. Vaderis's lead compound, known as VAD044, is a novel allosteric AKT-inhibitor which has Fast-Track designation granted by FDA. VAD044 is used for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), an Orphan disease for which there are no approved therapies. VAD044 enters Phase 3 trials in 2025 and is years ahead of all HHT competitors.
Date, time and room information
May 6, 15:00 - 15:15, room Montreal
Category
Clinical stage development company
Title of the presentation
Vaderis Therapeutics - First in HHT
Speaker information
| Name | Position | Institution |
|---|---|---|
| Nicholas Benedict | CEO and Co-Founder | Vaderis Therapeutics AG |
Host and event manager:
Logistics and marketing partner:
